Zimmer Biomet Q3 FY2026: sales up 3.1%, adjusted EPS flat, guidance raised
Zimmer Biomet delivered a steady quarter: revenue rose 3.1% to $2.063 billion and adjusted EPS of $1.90 matched consensus of $1.901, but GAAP EPS fell 13.8% to $1.00 and adjusted operating margin slipped to 25.1% from 26.5%. Management raised full-year organic growth and adjusted EPS guidance. Read it as broad-based growth in hips and SET offset by a shrinking knee business.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS of $1.00 fell 13.8%, while adjusted EPS of $1.90 was flat year over year and essentially matched the $1.901 consensus. The gap is mostly intangible asset amortization of $166.0 million, worth $0.69 a share, plus restructuring and acquisition-related costs. Adjusted net earnings were $362.8 million versus $191.6 million on a GAAP basis.
Revenue of $2.063 billion rose 3.1% on a reported basis and 3.7% in constant currency, against $2.001 billion a year ago. Hips ($536.5 million, +6.0%), SET ($578.3 million, +6.8%) and Technology & Data, Bone Cement and Surgical ($180.6 million, +11.9%) did the lifting. Knees, still the largest line at $767.5 million, fell 3.1%.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-04
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.